{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:45:56Z","timestamp":1791755156805,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jfo.2026.105002","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:17:16Z","timestamp":1791469036000},"page":"105002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of regenerative strategies versus traditional anti-inflammatory agents for moderate-to-severe dry eye disease: A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Y.","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-5989","authenticated-orcid":false,"given":"C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.105002_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Wolffsohn","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0010","first-page":"CD009729","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfo.2026.105002_bib0015","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ophtha.2017.08.029","article-title":"Inflammation in dry eye disease: how do we break the cycle?","volume":"124","author":"Rhee","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105002_bib0020","first-page":"CD010051","article-title":"Topical cyclosporine a therapy for dry eye syndrome","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfo.2026.105002_bib0025","doi-asserted-by":"crossref","first-page":"DES7","DOI":"10.1167\/iovs.17-23475","article-title":"Definition and diagnostic criteria of dry eye disease: historical overview and future directions","volume":"59","author":"Shimazaki","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2026.105002_bib0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III: digest","volume":"279","author":"Stapleton","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","article-title":"Blood derived eye drops for the treatment of cornea and ocular surface diseases","volume":"56","author":"Giannaccare","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jfo.2026.105002_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III: management and therapy","volume":"279","author":"Jones","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","article-title":"Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca","volume":"27","author":"Fox","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfo.2026.105002_bib0050","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","article-title":"Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis","volume":"56","author":"Kim","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICU.0000000000000768","article-title":"Alternative therapies for dry eye disease","volume":"32","author":"Mittal","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0060","first-page":"CD015070","article-title":"Topical corticosteroids for dry eye","volume":"10","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfo.2026.105002_bib0065","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1089\/jop.2023.0063","article-title":"Surgical procedures in the treatment of dry eye disease","volume":"39","author":"M\u00f8ller-Hansen","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0070","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4103\/IJO.IJO_2647_22","article-title":"5-fluorouracil as a targeted lacrimal gland therapy for chronic stevens-johnson syndrome: a pilot study","volume":"71","author":"Singh","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jtos.2020.11.013","article-title":"Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease","volume":"19","author":"M\u00f8ller-Hansen","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2026.105002_bib0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/aos.15629","article-title":"Role of stem cells in regenerative treatment of dry eye disease caused by lacrimal gland dysfunction","volume":"101","author":"Jackson","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2024.0101","article-title":"Water-free cyclosporine ophthalmic solution vs vehicle for dry eye disease: a randomized clinical trial","volume":"142","author":"Peng","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12886-025-04078-9","article-title":"Efficacy of topical mesenchymal stem cell exosome in Sj\u00f6gren's syndrome-related dry eye: a randomized clinical trial","volume":"25","author":"Habibi","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtos.2023.11.007","article-title":"Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"31","author":"M\u00f8ller-Hansen","year":"2024","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2026.105002_bib0100","doi-asserted-by":"crossref","first-page":"e001857","DOI":"10.1136\/bmjophth-2024-001857","article-title":"Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial","volume":"9","author":"Jongkhajornpong","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/ICO.0000000000003795","article-title":"The effect of autologous serum tears 50% on the ocular surface of patients with severe dry eye disease due to sjogren syndrome: a prospective, double-blind, randomized, controlled, contralateral eye study","volume":"44","author":"Bachtalia","year":"2025","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2026.105002_bib0110","article-title":"Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye","volume":"103","author":"Avila","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0115","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/DDDT.S370559","article-title":"Cyclosporine a (0.05%) ophthalmic gel in the treatment of dry eye disease: a multicenter, randomized, double-masked, phase III, COSMO trial","volume":"16","author":"Peng","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jop.2022.0119","article-title":"A multicenter, randomized, double-blind evaluation of the efficacy of TJO-087 versus 0.05% cyclosporine a in moderate to severe dry eye","volume":"39","author":"Eom","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0125","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/02713683.2012.674609","article-title":"Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome","volume":"37","author":"Urzua","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jfo.2026.105002_bib0130","doi-asserted-by":"crossref","first-page":"e34923","DOI":"10.1097\/MD.0000000000034923","article-title":"A randomized controlled trial involving college student: comparing 0.15% hyaluronic acid with 0.05% cyclosporine a and 3% diquafosol sodium in the treatment of dry eye","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jfo.2026.105002_bib0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clinthera.2020.12.023","article-title":"Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a multicenter phase II clinical study","volume":"43","author":"Peng","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0145","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.12998\/wjcc.v11.i28.6774","article-title":"Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome","volume":"11","author":"Zheng","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jfo.2026.105002_bib0150","doi-asserted-by":"crossref","first-page":"e16710","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jfo.2026.105002_bib0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0160","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-014-2599-1","article-title":"The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study","volume":"252","author":"Celebi","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0165","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0175","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin a phase 2 study group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105002_bib0180","first-page":"e88140","article-title":"Comparative evaluation of autologous platelet-rich plasma and artificial tears for treatment of chronic evaporative dry eye patients: a prospective interventional study","volume":"17","author":"Singh","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jfo.2026.105002_bib0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0190","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jfo.2026.105002_bib0195","first-page":"e1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.jfo.2026.105002_bib0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/jop.2024.0169","article-title":"Safety and efficacy of 0.1% cyclosporine solutions in dry eye syndrome: a systematic review and meta-analysis of randomized clinical trials","volume":"41","author":"Aleksander-Ivanov","year":"2025","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2026.105002_bib0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10792-025-03570-x","article-title":"Efficacy of topical cyclosporine a in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Lu","year":"2025","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105002_bib0210","doi-asserted-by":"crossref","first-page":"1500160","DOI":"10.3389\/fmed.2024.1500160","article-title":"Blood component therapy for dry eye disease: a systematic review and network meta-analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med (Lausanne)"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:07:36Z","timestamp":1791752856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551226002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0181551226002287"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.105002","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of regenerative strategies versus traditional anti-inflammatory agents for moderate-to-severe dry eye disease: A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.105002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105002"}}